TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05761470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle.~Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel
Study: NCT06334705

Intervention type: OTHER
Group type: OTHER
Intervention: blood test, food collection, hair collection, calcium scan, etc.
Description: everything is specified during the phone call and in the consent form to be signed
Study: NCT05180890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton
Description: Danavorexton intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton
Description: Danavorexton intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion.
Study: NCT05356650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization
Description: The patient will be in a prone position. With one hand, the physiotherapist will fix the sacrum and place the fingers of her other hand under the anterior superior iliac spine. The therapist then pull the ilium on the sacrum and will instruct the patient to do press-ups. Treatment will be given with frequency of 3 sets with 10 repetitions on sacroiliac joint 3 times a week for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: PNF stretching will be performed using contract-relax techniques of agonists in supine, prone and side-lying. Contract-relax will be applied with a 6-second contraction with 80% force of the maximal isometric contraction on the muscles (iliopsoas, hamstrings and gluteal muscles) and will be followed by a 15-second passive static stretching in the opposite direction of that muscles. Three sets of stretching of each muscle will be performed for each position with the frequency of 3 times a week for 6 weeks.~Patient will be in supine, prone, side lying. Both groups will receive a baseline treatment (Moist Heat Pack for 10 minutes and 10 minutes of Ultrasound (0.75 MHz, continuous wave)
Study: NCT06226337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listen music
Description: During hysterosalpingography, women were listened to the Acemaşiran maqam as music via MP4 players and headphones.
Study: NCT05164198

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab and its biosimilars
Description: 1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab and its biosimilars
Description: 1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological: Etanercept and its biosimilars
Description: 1. Active substance: Etanercept~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 50mg/mL~4. Route of administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: Etanercept and its biosimilars
Description: 1. Active substance: Etanercept~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 50mg/mL~4. Route of administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab
Description: 1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: 1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab biosimilar
Description: 1. Active substance: Infliximab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 120mg/mL~4. Route of administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab biosimilar
Description: 1. Active substance: Infliximab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 120mg/mL~4. Route of administration: Subcutaneous injection
Study: NCT06517121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized Experimental Transcranial Direct Current Stimulation (tDCS)
Description: This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants will receive 20 minutes of active stimulation with a 2mA intensity over personalized brain regions based on the particular neural correlates of socio-affective processing.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants assigned to the sham control group will only receive 30 seconds of active stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Experimental Transcranial Direct Current Stimulation (tDCS)
Description: This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants will receive 20 minutes of active stimulation with a 2mA intensity with anode placed over F3.
Study: NCT05973123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Nature Outings
Description: A 6 week nature-based intervention for pediatric anxiety. Every other week group outings for families in nature, alternating with every other week nature-based goals for families at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Outings
Description: 6 weeks of weekly outings into nature. These will be supported by the research team through a weekly text message and written materials on skill building and activities to do outdoors.
Study: NCT05646576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: * Palliative care (PC) intervention tailored to ACT recipients and addressing multiple PC domains with the input of ACT clinical experts, PC clinicians, and patients and caregivers.~* Domains discussed include therapeutic relationship, symptom management, prognostic awareness and illness understanding, coping with illness, treatment decision-making, EOL care.~* The palliative care intervention will be refined for the randomized control trial based on the feedback from the open pilot.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard care for ACT per the treating team.
Study: NCT05962190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: High fat (\~60% of total energy intake) diet enriched with either SFA or UFA
Study: NCT04876131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzylpenicillin - single dose
Description: Participants will receive a single dose of IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzylpenicillin - three days
Description: Participants will receive three days of this IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours. For severe infections, use up to 60 mg/kg (maximum 2.4 g) every 4-6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin - single dose
Description: Participants will receive a single dose of IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin - three days
Description: Participants will receive three days of this IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefalexin - post single dose of IV antibiotics for the remaining two days
Description: Oral antibiotic will be as per local guidelines. i.e. Cefalexin 25mg/kg (maximum dosage 500mg) 4 times a day or 33mg/kg (maximum dosage 500mg) 3 times a day
Study: NCT06404879

Intervention type: OTHER
Intervention: determining scores with tests
Description: Parents of children preparing for the operation will be given a child and family information form and STAI-I and STAI-II (State-Trait Anxiety Scale) scale forms and will be asked to fill them out themselves.~An anesthesia technician blind to the content of the study will calculate and take notes on the children\&#39;s anxiety levels, according to the m-YPAS (modified Yale Preoperative Anxiety) scale, in the preoperative waiting room (T1) and when the anesthesia ventilation mask is shown (T4).~FLACC (Face, Legs, Activity, Cry, Consolabilityscale) scores and spO2, pulse values and complications such as nausea, vomiting and desaturation at the 5th, 10th, 20th and 30th minutes of all children taken to the recovery unit in the postoperative period will be recorded by the recovery unit nurse. . Children who are thought to have pain according to the FLACC score will be given 0.5 mg/kg meperidine as rescue analgesia and a note will be taken.
Study: NCT05443074

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face to face intervention group
Description: Participants of this group will participate in a one 15 minutes face to face session where they will receive information about anatomy, functions and dysfunctions of the pelvic floor. During the session, some teaching materials will be used (an anatomical model, prototype simulator of the functions of the PFM, posters, videos and images), in order to facilitate the learning of women about how to contract their PFM and how to avoid urinary loss by contracting their muscles.~At the end of the session, the participants will have time to ask their questions and will receive a home booklet reinforcing the information given during the session including instructions for them to perform a PFM contraction during daily live situations that generate an increased intra-abdominal pressure, such as coughing, sneezing, weight lifting and other activities, as well as strategies to inhibit urge urinary incontinence (UI).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote intervention group
Description: Participants of this group will be referred to a room with a computer (inside the rehabilitation center) to participate in a one 15 minutes real time remote session, where they will receive information about anatomy, functions and dysfunctions of the pelvic floor. During the session, some teaching materials will be used (an anatomical model, prototype simulator of the functions of the PFM, posters, videos and images), in order to facilitate the learning of women about how to contract their PFM and how to avoid urinary loss by contracting their muscles.~At the end of the session, the participants will have time to ask their questions and will receive a home booklet reinforcing the information given during the session including instructions for them to perform a PFM contraction during daily live situations that generate an increased intra-abdominal pressure, such as coughing, sneezing, weight lifting and other activities, as well as strategies to inhibit urge UI.
Study: NCT06012981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: The treatment is based on a variant of CBT, as briefly referred to before, ACT. In short, the treatment consists of identifying central and important areas of life, and how to approach these even though you are also struggling with persistent and challenging problems. In this study, the treatment intervention is flexibly constructed, focusing on several central principles based on ACT. These can be applied during one or numerous sessions.~The intervention is a flexible application of clinical functional analysis, as well as a couple of selected interventions which, in terms of experience and in previous studies, have been shown to work well for the current group (24-hour psychiatric patients with complex problems) and which are individually adaptable to the nature of the problem and degree.
Study: NCT06358248

Intervention type: DEVICE
Intervention: Physician-modification of Valiant Captivia Endograft (Medtronic, Minneapolis, MN-USA).
Description: On a sterile back-table a Valiant Captivia thoracic graft is deployed. A dotted line is drawn to mark the graft anterior 0° degree, and fabric holes are performed with cautery in the desired position. The fenestrations need to be 6x6 mm for the renals and 8x8 mm for superior mesenteric artery (SMA) and celiac trunk (CT), and are reinforced with the tip of a 0.018 guidewire through a continuous 5-0 locking suture.~A posterior constraining wire is created to reduce the diameter of the graft by 20-30%, in order to allow rotation during the deployment phase. The four 8 markers on the top of the graft are carefully removed with a scalpel; one of these is modified as an S and re-sutured on the anterior aspect at 0 degree position, with a 5-0 prolene continuous suture. This S marker will allow anteroposterior graft orientation. Finally, the graft is re-sheathed and deployed.
Study: NCT04964349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids Acting Locally
Description: topical application of jessener solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids Acting Locally
Description: topical application of jessener solution
Study: NCT05235282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQoro
Description: An acrylic mouth guard with a pulling loop. The mouth guard is placed in the mouth of the patient on the outside of the teeth. The therapist pulls the loop in different directions and the patient try to close his/her mouth on the mouth guard to keep it inside the mouth.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for swallowing function
Description: Cuff deflation, speaking valve, masako exercises, shaker exercises, coughing, stimulation of the oral cavity, neuromuscular electrical stimulation, postural control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care for swallowing function
Description: Cuff deflation, speaking valve, masako exercises, shaker exercises, coughing, stimulation of the oral cavity, neuromuscular electrical stimulation, postural control
Study: NCT05443074

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants of this group will be assessed in the same time points of the participants of the two other groups. They will not receive any intervention or information about pelvic floor anatomy, functions and dysfunctions of the pelvic floor, however after the last assessment (20 days after) for ethical reasons they will receive the same intervention.
Study: NCT06432907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor tasks
Description: During the study session, the patient will sit at a table in front of a computer monitor. The stereoEEG electrodes will be connected to the Neurovisor-BMM52 electroencephalograph (Medical Computer Systems, Russia) and to a computer with a software for recording and decoding brain signals (BCI classifier). One microsensor (Ascension TrekStar, Ascension Technology, USA) and two disposable cutaneous electrodes (connected to the Neurovisor-BMM52 system) will be put on each patient's hand for electromyogram recording.~The session consists from 3 blocks (1-3). The participant is asked to:~1. execute simple motor tasks (thumbs up, open hand or clench hand into fist - 30 times with each hand with 5-second brakes), according to the instruction on the computer screen;~2. to imagine the same movements - 30 times with each hand with 5-second brakes;~3. to imagine the same movements with the feedback (brain-computer interface control).~The blocks are separated by 5-minute brakes.
Study: NCT06439693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Anti-microtubule agent, via intravenous (into the vein) infusion per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Anti-microtubule agent, via intravenous infusion per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Anti-microtubule agent, via intravenous infusion per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phesgo
Description: Pertuzumab plus trastuzumab plus hyaluronidase-zzxf, 10 or 15mL single-dose vial, via subcutaneous (under the skin) injection per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: HER2-targeted antibody-drug conjugate, 16 or 100 mg single-use vials, via intravenous infusion per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Recombinant humanized monoclonal antibody, 20mL single-use vial, via intravenous infusion per institutional guidelines.
Study: NCT05675813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP+selinexor+5-Azacitidine
Description: Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T1 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and selinexor 40mg or 60mg qw (d-7, 1, 8) by traditional 3+3 dose escalation methods and decide RP2D of selinexor.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP+duvelisib+5-Azacitidine
Description: Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T2 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and duvelisib 25mg or 50mg bid (d1-14) by traditional 3+3 dose escalation methods and decide RP2D of duvelisib.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle.
Study: NCT06439693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: HER2-directed antibody drug conjugate, 100mg vial, via intravenous infusion per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Subcutaneous Subcutaneous
Description: Humanized IgG1 kappa monoclonal antibody, 6mL vial, via subcutaneous injection per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tyrosine Kinase HER2 Inhibitor, 50 or 150mg tablet taken orally per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Humanized IgG1 kappa monoclonal antibody, 150 mg single-dose vial, via intravenous infusion per institutional guidelines.
Study: NCT04686825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 2.5mg (Fasting)
Description: Test drug l : DA-8010 2.5mg (Fasting)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 2.5mg (Fed)
Description: Test drug ll : DA-8010 2.5mg (Fed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 5mg (Fasting)
Description: Test drug llI : DA-8010 5mg (Fasting)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 5mg (Fed)
Description: Test drug lV : DA-8010 5mg (Fed)
Study: NCT05977556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined neuromuscular exercise training and 'sit less, move more' program
Description: Neuromuscular strength training: The experimental group will receive up to 24 sessions of neuromuscular strength training led by a physical therapist with expertise in geriatrics and movement behaviors. The program includes exercises such as pelvic lifts, lunges, step-ups, squats, and sit-stands. The difficulty level will progressively increase using techniques like manual resistance, dumbbells, and unstable surfaces.~Sedentary behavior intervention: The experimental group will also undergo a sedentary behavior intervention based on social cognitive theory. It involves weekly coaching sessions to enhance self-efficacy in reducing sedentary time and increasing light-intensity activity throughout the day. Participants will be provided with a wrist-worn Fitbit activity monitor for daily feedback and to track adherence to the intervention. The aim is to encourage participants to sit less and move more throughout their waking hours.
Study: NCT04999449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Intranasal scopolamine at 0.2 mg or 0.4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Intranasal scopolamine at 0.2 mg or 0.4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intranasal saline placebo
Study: NCT05699525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized MAYA Mobile App
Description: All new material in the personalized condition will be introduced within the first four weeks and will contain modules targeting participant's personal symptom profiles. The remaining two weeks in the personalized condition will consist of practicing previously learned skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General MAYA Mobile App
Description: New material will be introduced to participants over all the six weeks of the intervention and will include all application modules.